chr17-36537715-CTGTT-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP5
The NM_001346754.2(PIGW):c.617_620delTTTG(p.Val206fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.000195 in 1,614,162 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00019 ( 0 hom. )
Consequence
PIGW
NM_001346754.2 frameshift
NM_001346754.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.65
Genes affected
PIGW (HGNC:23213): (phosphatidylinositol glycan anchor biosynthesis class W) The protein encoded by this gene is an inositol acyltransferase that acylates the inositol ring of phosphatidylinositol. This occurs in the endoplasmic reticulum and is a step in the biosynthesis of glycosylphosphatidylinositol (GPI), which anchors many cell surface proteins to the membrane. Defects in this gene are a cause of the age-dependent epileptic encephalopathy West syndrome as well as a syndrome exhibiting hyperphosphatasia and cognitive disability (HPMRS5). [provided by RefSeq, Jul 2017]
MYO19 (HGNC:26234): (myosin XIX) Enables actin binding activity. Involved in regulation of cytokinesis and regulation of mitochondrial fission. Acts upstream of or within mitochondrion migration along actin filament. Located in cytosol and mitochondrial outer membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-36537715-CTGTT-C is Pathogenic according to our data. Variant chr17-36537715-CTGTT-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 377301.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=4, Pathogenic=1, Likely_pathogenic=4}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PIGW | NM_001346754.2 | c.617_620delTTTG | p.Val206fs | frameshift_variant | 2/2 | ENST00000614443.2 | NP_001333683.1 | |
PIGW | NM_001346755.2 | c.617_620delTTTG | p.Val206fs | frameshift_variant | 2/2 | NP_001333684.1 | ||
PIGW | NM_178517.5 | c.617_620delTTTG | p.Val206fs | frameshift_variant | 2/2 | NP_848612.2 | ||
MYO19 | XM_047436823.1 | c.-295-3615_-295-3612delAACA | intron_variant | XP_047292779.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PIGW | ENST00000614443.2 | c.617_620delTTTG | p.Val206fs | frameshift_variant | 2/2 | 1 | NM_001346754.2 | ENSP00000482202.1 |
Frequencies
GnomAD3 genomes AF: 0.000204 AC: 31AN: 152168Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
31
AN:
152168
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000255 AC: 64AN: 251406Hom.: 0 AF XY: 0.000243 AC XY: 33AN XY: 135900
GnomAD3 exomes
AF:
AC:
64
AN:
251406
Hom.:
AF XY:
AC XY:
33
AN XY:
135900
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000194 AC: 283AN: 1461876Hom.: 0 AF XY: 0.000194 AC XY: 141AN XY: 727242
GnomAD4 exome
AF:
AC:
283
AN:
1461876
Hom.:
AF XY:
AC XY:
141
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000204 AC: 31AN: 152286Hom.: 0 Cov.: 32 AF XY: 0.000228 AC XY: 17AN XY: 74460
GnomAD4 genome
AF:
AC:
31
AN:
152286
Hom.:
Cov.:
32
AF XY:
AC XY:
17
AN XY:
74460
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:5Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Dec 02, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 15, 2022 | Has not been previously published as pathogenic or benign to our knowledge; Frameshift variant predicted to result in protein truncation, as the last 229 amino acids are replaced with 2 different amino acids - |
Hyperphosphatasia with intellectual disability syndrome 5 Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | May 03, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 05, 2022 | This sequence change creates a premature translational stop signal (p.Val206Glyfs*3) in the PIGW gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 299 amino acid(s) of the PIGW protein. This variant is present in population databases (rs753385776, gnomAD 0.09%). This variant has not been reported in the literature in individuals affected with PIGW-related conditions. ClinVar contains an entry for this variant (Variation ID: 377301). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 29, 2024 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 22, 2022 | The c.617_620delTTTG (p.V206Gfs*3) alteration, located in exon 2 (coding exon 1) of the PIGW gene, consists of a deletion of 4 nucleotides from position 617 to 620, causing a translational frameshift with a predicted alternate stop codon after 3 amino acids. This alteration occurs at the 3' terminus of the PIGW gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 299 amino acids of the protein. Premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). Based on data from gnomAD, the c.617_620delTTTG allele has an overall frequency of 0.02% (69/282804) total alleles studied. The highest observed frequency was 0.08% (29/35438) of Latino alleles. Based on the available evidence, this alteration is classified as pathogenic. - |
Global developmental delay;C2981150:Cleft palate;C4023165:Abnormal skeletal morphology Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Dec 03, 2018 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 03, 2023 | Variant summary: PIGW c.617_620delTTTG (p.Val206GlyfsX3) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay. The variant allele was found at a frequency of 0.00025 in 251406 control chromosomes.To our knowledge, no occurrence of c.617_620delTTTG in individuals affected with Hyperphosphatasia With Mental Retardation Syndrome 5 and no experimental evidence demonstrating its impact on protein function have been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified as VUS (n=2), Likely Pathogenic (n=3) and Pathogenic (n=1). Based on the evidence outlined above and the fact that there is not enough evidence to establish loss-of-function as a mechanism of disease for this gene, the variant was classified as uncertain significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at